Related Experiment Video
Updated: Mar 21, 2026
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Matthew K Ito1,2, Raul D Santos3
1Sanofi US, Bridgewater, NJ, USA.
Insights
New PCSK9 inhibitors offer significant cholesterol reduction for patients unresponsive to statins. These monoclonal antibodies show promise in managing hypercholesterolemia and reducing cardiovascular disease risk.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Pharmacology
Background:
- Current hypercholesterolemia guidelines recommend lifestyle changes and lipid-modifying therapy to mitigate cardiovascular disease (CVD) risk.
- Statins are the frontline treatment, but some patients do not achieve optimal lipid reduction or experience intolerance.
- The PCSK9 gene has emerged as a key therapeutic target for managing hypercholesterolemia.
Purpose of the Study:
- To review the development and potential of PCSK9 inhibitors, particularly monoclonal antibodies, for hypercholesterolemia treatment.
- To evaluate the efficacy and safety of newly approved PCSK9 inhibitors like alirocumab and evolocumab.
- To discuss the role of PCSK9 inhibition in patients with suboptimal statin response or intolerance.
Main Methods:
- Review of current literature and clinical development of PCSK9 inhibitors.
- Analysis of data on approved monoclonal antibodies (alirocumab, evolocumab) and those in development (bococizumab).
- Examination of lipid-lowering effects and safety profiles of PCSK9 inhibitors.
Main Results:
- Alirocumab, evolocumab, and bococizumab significantly reduce low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B, and lipoprotein(a).
- PCSK9 inhibitors demonstrate a robust reduction in atherogenic cholesterol levels with a generally good safety profile.
- Long-term outcome trials are ongoing to assess sustained efficacy, safety, and impact on major cardiovascular events.
Conclusions:
- PCSK9 inhibitors represent a promising novel therapeutic class for hypercholesterolemia management.
- These agents are particularly beneficial for patients with statin intolerance, contraindications, familial hypercholesterolemia, or those not reaching lipid goals on statins.
- Further research through outcome trials will solidify the long-term clinical benefits and safety of PCSK9 inhibition in cardiovascular risk reduction.
Abstract:
Current guidelines for hypercholesterolemia treatment emphasize lifestyle modification and lipid-modifying therapy to reduce the risk for cardiovascular disease. Statins are the primary class of agents used for the treatment of hypercholesterolemia. Although statins are effective for many patients, they fail to achieve optimal reduction in lipids for some patients, including those who have or are at high risk for cardiovascular disease. The PCSK9 gene was identified in the past decade as a potential therapeutic target for the management of patients with hypercholesterolemia. Pharmacologic interventions to decrease PCSK9 levels are in development, with the most promising approach using monoclonal antibodies that bind to PCSK9 in the plasma. Two monoclonal antibodies, alirocumab and evolocumab, have recently been approved for the treatment of hypercholesterolemia, and a third one, bococizumab, is in phase 3 clinical development. All 3 agents achieve significant reductions in levels of low-density lipoprotein cholesterol, as well as reductions in non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a). Long-term outcome trials are under way to determine the sustained efficacy, safety, and tolerability of PCSK9 inhibitors and whether this novel class of agents decreases the risk for major cardiovascular events in patients on lipid-modifying therapy. Available data suggest that PCSK9 inhibitors provide a robust reduction in atherogenic cholesterol levels with a good safety profile, especially for patients who fail to obtain an optimal clinical response to statin therapy, those who are statin intolerant or have contraindications to statin therapy, and those with familial hypercholesterolemia.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:29Pharmacogenomics: Identification of New Drug Targets
01:26Atherosclerosis III: Management
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:26Coronary Artery Disease IV: Preventive Measures
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...